Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
暂无分享,去创建一个
Denis Lacombe | Johan M Kros | R. Stupp | M. J. van den Bent | A. Brandes | T. Gorlia | D. Lacombe | E. Raymond | M. Heinrich | J. Kros | P. Fumoleau | C. Dittrich | Roger Stupp | Martin J van den Bent | Christian Dittrich | Thierry Gorlia | Bruno Coudert | Michael C Heinrich | Marc Frenay | Eric Raymond | Pierre Fumoleau | M. Frénay | P. Clement | Paul M J Clement | Alba A Brandes | Roy Rampling | B. Coudert | R. Rampling
[1] C. Heldin,et al. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures , 2006, Oncogene.
[2] R. Carroll,et al. Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. , 1998, Neurosurgery.
[3] W. Richardson,et al. Control of progenitor cell number by mitogen supply and demand , 2001, Current Biology.
[4] W. Elmquist,et al. Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated Efflux , 2003, Journal of Pharmacology and Experimental Therapeutics.
[5] C. James,et al. Amplification of the Platelet‐Derived Growth Factor Receptor‐A (PDGFRA) Gene Occurs in Oligodendrogliomas with Grade IV Anaplastic Features , 2000, Journal of neuropathology and experimental neurology.
[6] D. Louis,et al. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. , 2001, Genes & development.
[7] Darell D. Bigner,et al. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.
[8] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[9] J. Fletcher,et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. J. van den Bent,et al. Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. , 2002, Annals of Oncology.
[11] D. Louis,et al. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. , 1996, Cancer research.
[12] Howard A. Fine,et al. Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.
[13] Y. Shoshan,et al. Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[14] S. Bates,et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib , 2006, Clinical pharmacology and therapeutics.
[15] R. Stupp,et al. European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] J. Menten,et al. Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. , 2002, European Journal of Cancer.
[17] G. Dresemann. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] R. Miller,et al. Constitutive Expression of Growth-related Oncogene and Its Receptor in Oligodendrogliomas , 2001, Neurosurgery.
[19] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Tracy T Batchelor,et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.
[21] I. Pollack,et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. , 2007, Neuro-oncology.
[22] Jing Li,et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients , 2007, Cancer biology & therapy.
[23] C. Heldin,et al. Activated platelet‐derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell line , 1994, Journal of cellular physiology.
[24] K. Zitnay,et al. K252a inhibits proliferation of glioma cells by blocking platelet-derived growth factor signal transduction. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] A. Guha,et al. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop , 1995, International journal of cancer.
[26] T R Fleming,et al. One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.
[27] M J Gleason,et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Raff,et al. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium , 1983, Nature.